Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL6434346

N=C(N)Nc1ncc(Cl)c2ccc(C(=O)N(CC(=O)O)c3ccccc3)cc12.O=C(O)C(F)(F)F

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
F2 P00734 7/20 0.40
PLAU P00749 3/20 0.40
PRSS12 P56730 1/20 0.36
KLK1 P06870 1/20 0.36
KLK5 Q9Y337 1/20 0.36
F10 P00742 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
ALDH1A1 P00352 2/20 0.33
HTR5A P47898 1/20 0.33
MAPK3 P27361 1/20 0.33
CXCR2 P25025 1/20 0.33
KMT2A Q03164 1/20 0.33
MLYCD O95822 1/20 0.33
PRSS1 P07477 1/20 0.33
PRSS2 P07478 1/20 0.33
PRSS3 P35030 1/20 0.33
BACE1 P56817 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7367488 0.94 PLAU (0.43) F2PLAUPRSS12F10SMN1; SMN2
SCHEMBL6433874 0.84 F2 (0.37) F2PLAUPRSS12F10SMN1; SMN2
Trifluoroacetic Acid SCHEMBL6437287 0.81 PLAU (0.64) PLAUSMN1; SMN2
SCHEMBL7365772 0.80 PRSS12 (0.37) F2PLAUPRSS12F10SMN1; SMN2
Trifluoroacetic Acid SCHEMBL6436650 0.79 CA1 (0.42) F2PLAUKLK1KLK5HTR5A
Trifluoroacetic Acid SCHEMBL6433433 0.79 PLAU (0.43) PLAU
Hydrochloric Acid SCHEMBL6432998 0.79 PLAU (0.44) PLAUPRSS1PRSS2PRSS3
SCHEMBL7403972 0.78 PLAU (0.44) F2PLAUPRSS12SMN1; SMN2ALDH1A1
Trifluoroacetic Acid SCHEMBL6434862 0.77 CTSA (0.42)
Trifluoroacetic Acid SCHEMBL6434344 0.77 KLK1 (0.38) PLAUKLK1KLK5F10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050026836-A1 Composition for the treatment of damaged tissue DACK KEVIN NEIL (GB) 2005-02-03 US disclosed
US-20030199440-A1 Composition for the treatment of damaged tissue PFIZER INC. 2003-10-23 US disclosed
EP-1077945-B1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER (US) 2003-01-08 EP disclosed
EP-1242120-A2 COMBINATIONS OF GROWTH FACTORS AND I:UPA OR I:MMP FOR THE TREATMENT OF DAMAGED TISSUE Pfizer Limited (GB) 2002-09-25 EP disclosed
WO-2001049309-A2 COMBINATIONS OF GROWTH FACTORS AND I: UPA OR I: MMP FOR THE TREATMENT OF DAMAGED TISSUE PFIZER LIMITED (GB) 2001-07-12 WO disclosed
EP-1077945-A1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER INC. (US) 2001-02-28 EP disclosed
US-6093731-A Isoquinolines PFIZER INC. 2000-07-25 US disclosed
WO-2000005214-A2 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER INC. (US) 2000-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199440-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 F2 350/4885PLAU 119/4885PRSS12 219/4885
US-20050026836-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 F2 350/4885PLAU 119/4885PRSS12 219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.